AVLAYAH's mechanism shows that current CNS biologic trials, which focus on plasma PK/PD and treat brain exposure as pharmacologically inaccessible, need CNS-specific PK models, potentially relying on serial CSF sampling or validated CNS imaging biomarkers as primary endpoints.

FDA approved AVLAYAH (tividenofusp alfa-eknm) on March 25, 2026 for Hunter syndrome with neurologic involvement, marking the first biologic engineered to cross the blood-brain barrier after IV administration.

The core mechanism uses transferrin receptor–mediated transcytosis, with the therapeutic payload fused to a TfR1-binding antibody fragment to enable brain uptake and CNS tissue release.

There is a risk that industry will overgeneralize AVLAYAH as a template, risking gaps in bioanalytical validation, CNS PK modeling, and compartment-specific safety monitoring in future trials, potentially echoing past ARIA-type safety signals in anti-amyloid programs.

AVLAYAH sets a precedent but does not solve broader CNS challenges; applying its success to diseases like Alzheimer's or ALS will require new infrastructure and frameworks beyond the Hunter syndrome model.

The approval demonstrates receptor-mediated transcytosis can deliver biologics into the CNS, challenging decades of trial design that assumed limited brain exposure and relied on downstream biomarkers rather than direct CNS exposure.

CNS penetration raises safety monitoring questions since CNS off-target effects may not appear in plasma and could emerge in CSF cytokines, neuroimaging changes, or cognitive assessments, underscoring a gap highlighted by ARIA experiences with amyloid-targeting therapies.

Regulators and sponsors should treat AVLAYAH as a proof of mechanism that requires CNS-specific bioanalytical standards, CSF PK sampling, and compartment-aware immunogenicity protocols to safely scale brain-shuttle therapies.

Two key questions for future brain-shuttle indications: (1) development of CNS PK/PD models tailored to specific indications and populations, and (2) assessment of CNS immunogenicity, potentially needing CSF ADA sampling and CNS-specific stopping rules, for which no finalized CNS-focused guidance exists yet.